AMVUTTRA™ significantly improved polyneuropathy1,2
Primary endpoint: change from baseline at 9 months in mNIS+71
- mNIS+7 is a composite measure that assesses motor strength, reflexes, sensation, nerve conduction, and postural blood pressure (score range 0 to 304)1
aMean mNIS+7 at baseline was 60.6 with AMVUTTRA and 74.6 with external placebo group.1
bBars represent SEM.
cN=number of evaluable patients.
dReversal defined as mNIS+7 change from baseline of <0 points.
CI=confidence interval; LS=least squares.
aMean mNIS+7 at baseline was 60.6 with AMVUTTRA and 74.6 with external placebo group.1
bBars represent SEM.
cN=number of evaluable patients.
dReversal defined as mNIS+7 change from baseline of <0 points.
CI=confidence interval; LS=least squares.
48% of patients treated with AMVUTTRA experienced reversald in neuropathy impairment from baseline at 18 months, compared with 4% of patients in the external placebo group.2,3
aMean mNIS+7 at baseline was 60.6 with AMVUTTRA and 74.6 with external placebo group.1
bBars represent SEM.
cN=number of evaluable patients.
dReversal defined as mNIS+7 change from baseline of <0 points.
CI=confidence interval; LS=least squares.
AMVUTTRA significantly improved quality of life2
AMVUTTRA helped to alleviate the burden of the disease, as measured by Norfolk QoL-DN1,2
- Norfolk QoL-DN is a patient-reported assessment that evaluates the effects of neuropathy in domains such as physical functioning, activities of daily living, symptoms, and autonomic function (score range -4 to 136)1
aNorfolk QoL-DN scores at baseline were 47.1 with AMVUTTRA and 55.5 with external placebo group.1
bBars represent SEM.
cN=number of evaluable patients.
aNorfolk QoL-DN scores at baseline were 47.1 with AMVUTTRA and 55.5 with external placebo group.1
bBars represent SEM.
cN=number of evaluable patients.
57% of patients treated with AMVUTTRA experienced improvement in quality of life from baseline at 18 months, compared with 10% of patients in the external placebo group.2
aNorfolk QoL-DN scores at baseline were 47.1 with AMVUTTRA and 55.5 with external placebo group.1
bBars represent SEM.
cN=number of evaluable patients.
- AMVUTTRA-treated patients experienced significant improvement in nutritional status from baseline at 18 months compared with placebo-treated patients, who experienced a decline (25.0 units, -115.7 units, respectively [p<0.001])2
- Improvement in mBMI vs placebo was observed after 1 dose of AMVUTTRA3
- Patients treated with AMVUTTRA maintained a better gait speed from baseline at 18 months compared with those treated with placebo (-0.024 m/sec, -0.264 m/sec, respectively [p<0.001])2
- R-ODS is a 24-item scale that evaluates limitations on everyday activities such as showering, going shopping, carrying a heavy object, walking up stairs, and/or walking outdoors (score range 0 to 48)4
- AMVUTTRA-treated patients were better able to perform activities of daily living compared with placebo-treated patients (LS mean change from baseline at 18 months was -1.5 and -9.9, respectively [p<0.001])2